韩特氏症治疗市场－全球产业规模、份额、趋势、机会、预测：按治疗方法、最终用户、地区和竞争格局划分，2021-2031年

全球韩特氏症治疗市场预计将从 2025 年的 14.1 亿美元成长到 2031 年的 19.4 亿美元，复合年增长率为 5.46%。

此领域专注于开发和推广治疗性介入（包括酵素替代疗法和新兴基因疗法），以治疗黏多醣症II型（一种由艾膦酸-2-硫酸酯酶缺乏引起的罕见遗传性疾病）。推动此领域发展的因素众多，例如新生儿筛检计画的广泛应用促进了早期疗育，以及有利于降低研发财务风险的法规结构（如孤儿药认定）。这种发展势头也体现在罕见疾病领域的活跃度上。美国製药商协会（PhRMA）在2024年报告称，监管机构已核准七种用于治疗罕见疾病的新型细胞和基因疗法，显示下一代生物製药的临床环境良好。

然而，药物难以穿过血脑障壁这一生理难题，对市场扩张构成了重大障碍。酵素替代疗法作为目前的标准疗法，往往无法缓解与严重神经系统疾病相关的进行性性认知衰退，限制了其临床疗效，也限制了现有产品能够有效治疗的患者群体。

市场驱动因素

基因治疗和基因组编辑技术的进步正在改变临床格局，为黏黏多醣症II型（MPSII）的潜在根治性治疗方法提供了可能。与慢性管理疗法不同，这些治疗方法旨在恢復功能性硫酸乙酰肝素酶-2（idronase-2-sulfatase）的产生，从而减轻疾病的系统性负担，并验证高价值的评估模型。这一转变得益于优先考虑罕见疾病的法规环境。美国食品药物管理局（FDA）报告称，2024年核准的55种新药中有28种是用于治疗上年度疾病，凸显了加速药物研发的努力。例如，Regenxbio公司在2024年9月发布的新闻稿显示，接受确定剂量RGX-121治疗的患者脑脊髓液中硫酸乙酰肝素D2S6的中位以金额为准降低了85%，证实了该疗法的疗效。

同时，血脑障壁穿越机制的创新解决了传统静脉酵素替代疗法一直无法克服的难题：无法治疗严重的神经病变症状。新兴技术利用受体介导的转运，主动将大分子治疗药物递送至受影响的中枢神经系统组织，从而实现预防进行性认知衰退的关键。正如Denali Therapeutics公司在2024年9月的新闻稿中所述，cibidenofusp alfa的I/II期临床试验显示，到第24週，脑脊髓液中血脑障壁平均降低了90%，这表明全身治疗可以有效治疗以前被认为无法治癒的神经系统症状。

市场挑战

治疗药物生理上无法穿过血脑障壁，是韩特氏症治疗全球市场成长的主要障碍。目前，标准疗法—酵素替代疗法—由于其庞大的分子结构阻碍了其渗透到中枢神经系统，因此对重度神经系统黏多醣症II型（韩特氏症）患者出现的进行性认知功能下降无效。这项限製造成了市场分化：一方面，身体症状得到控制；另一方面，神经系统疾病持续存在。这严重限制了现有生物製药的商业性潜力，因为最需要介入的患者无法获得全面的治疗。

这项科学挑战阻碍了市场成长，因为现有治疗方案无法满足巨大的未满足需求。设计能够绕过生理屏障的大分子药物十分复杂，不仅延缓了研发进度，也增加了生产商的风险。根据美国製药商协会（PhRMA）统计，截至2024年，该产业共有148种用于治疗遗传性疾病的药物正在研发中，但开发能够克服中枢神经系统屏障的治疗方法仍是研发领域的一大瓶颈。大量在研药物与缺乏脑渗透性核准之间存在的巨大差距，凸显了血脑障壁如何持续限制市场发展和商业性扩充性。

市场趋势

体外干细胞基因治疗方法的发展正在创造一种独特的治疗层级，其疗效超越了传统的体内病毒载体疗法。此策略包括改造自体造血干细胞，使其表达艾膦酸-2-硫酸酯酶，诱导其分化为小胶质细胞，并将该酶直接递送至大脑，从而实现中枢神经系统的持续修復，同时降低全身免疫抗原性的风险。伦敦大学学院于2025年11月发表的一篇论文详细阐述了这项发现：接受这种新型Exavio疗法的患者在移植后9个月，其语言能力、运动能力和认知发育均显着改善，展现出阻止神经退化进展的潜力。

此外，神经丝轻链生物标记在临床试验中的引入，正将检验重点从代谢基材转向神经元健康的直接测量。验证神经保护作用对于神经病理性表型的治疗方法至关重要，而神经丝轻链可提供轴突损伤的量化指标，从而比长期认知功能评估更快地评估疗效。根据纳斯达克2025年2月的一篇报导，一项tividenofusp alfa的I/II期临床试验显示，在中位追踪两年后，神经丝轻链水平显着且持续下降，证实了该生物标誌物在证明临床价值方面的实用性。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：韩特氏症治疗的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗方法（酵素替代疗法、造血干细胞移植）
  • 依最终使用者（医院/诊所、门诊中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美韩特氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲韩特氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区韩特氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲韩特氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲韩特氏症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球韩特氏症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Takeda Pharmaceutical Co Ltd
• F Hoffmann-La Roche AG
• Abbott Laboratories Inc
• Johnson & Johnson
• GSK PLC
• Bayer AG
• Novartis AG
• Pfizer Inc
• Zimmer Biomet Holdings Inc
• Sangamo Therapeutics, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Hunter Syndrome Treatment Market is projected to expand from USD 1.41 Billion in 2025 to USD 1.94 Billion by 2031, registering a CAGR of 5.46%. This sector focuses on the development and distribution of therapeutic interventions, including enzyme replacement therapies and emerging gene-based treatments, designed to manage Mucopolysaccharidosis II, a rare genetic disorder resulting from iduronate-2-sulfatase deficiency. Growth is underpinned by robust drivers such as the wider adoption of newborn screening programs facilitating early intervention and favorable regulatory frameworks, like orphan drug designations, that reduce R&D financial risks. This momentum is reflected in the rare disease sector's activity; the Pharmaceutical Research and Manufacturers of America noted in 2024 that regulatory agencies approved seven new cell and gene therapies for rare conditions, indicating a clinical environment conducive to next-generation biologics.

However, market expansion faces a substantial obstacle regarding the physiological difficulty of delivering therapeutics across the blood-brain barrier. Current standard-of-care enzyme replacement therapies frequently fail to mitigate the progressive cognitive decline linked to the severe, neuronopathic form of the disease, which limits clinical efficacy and restricts the patient population that can be effectively treated with existing products.

Market Driver

Advancements in gene therapy and genome editing are transforming the clinical landscape by providing potential one-time curative treatments that target the genetic origins of Mucopolysaccharidosis II. Unlike chronic management options, these modalities seek to restore functional iduronate-2-sulfatase production, thereby reducing the disease's systemic burden and validating high-value valuation models. This transition is bolstered by a regulatory environment prioritizing orphan conditions; the U.S. Food and Drug Administration reported that 28 of the 55 novel drugs approved in the previous year were for rare diseases in 2024, underscoring a commitment to expediting development. Clinical progress is illustrated by Regenxbio Inc.'s September 2024 press release, which reported that patients receiving the pivotal dose of RGX-121 achieved a median 85% reduction in cerebrospinal fluid heparan sulfate D2S6, confirming the approach's therapeutic viability.

Simultaneously, innovations in blood-brain barrier delivery mechanisms are addressing the historical limitations of intravenous enzyme replacement therapies, which traditionally fail to treat the disorder's severe neuronopathic symptoms. Emerging technologies are utilizing receptor-mediated transport to actively ferry large therapeutic molecules across the blood-brain barrier to reach affected central nervous system tissues, a capability vital for preventing progressive cognitive decline. As reported in a September 2024 press release by Denali Therapeutics Inc., a Phase 1/2 study of tividenofusp alfa demonstrated a 90% mean reduction in cerebrospinal fluid heparan sulfate by Week 24, proving that systemic treatments can effectively target neurological symptoms previously deemed untreatable.

Market Challenge

The physiological inability of therapeutic agents to traverse the blood-brain barrier constitutes a major obstacle to the growth of the Global Hunter Syndrome Treatment Market. Standard-of-care enzyme replacement therapies currently feature large molecular structures that prevent central nervous system penetration, rendering them ineffective against the progressive cognitive decline seen in the severe, neuronopathic form of Mucopolysaccharidosis II. This limitation creates a bifurcated market where somatic symptoms are managed while neurological pathology persists, significantly capping the commercial potential of existing biologics by failing to provide a comprehensive cure for the patients most in need of intervention.

This scientific hurdle restricts market growth by perpetuating a high level of unmet clinical need that current portfolios cannot satisfy. The complexity involved in engineering large-molecule drugs to bypass physiological barriers retards development timelines and elevates the risk profile for manufacturers. According to the Pharmaceutical Research and Manufacturers of America, although the industry had 148 medicines in development for genetic disorders in 2024, successfully formulating therapies that can overcome central nervous system barriers remains a significant operational bottleneck. This gap between broad pipeline activity and the scarcity of brain-penetrant approvals highlights how the blood-brain barrier continues to limit the advancement and commercial scalability of the market.

Market Trends

The development of Ex Vivo Stem Cell Gene Therapy approaches is creating a distinct therapeutic class that operates beyond standard in vivo viral vector modalities. This strategy involves modifying autologous hematopoietic stem cells to express iduronate-2-sulfatase, enabling them to differentiate into microglia and deliver enzymes directly to the brain, which mitigates systemic immunogenicity risks while ensuring durable central nervous system correction. As detailed in a November 2025 article by University College London, a patient treated with this novel ex vivo therapy exhibited dramatic improvements in speech, agility, and cognitive development nine months post-transplant, validating its potential to arrest neurodegenerative progression.

Additionally, the integration of Neurofilament Light Chain biomarkers in clinical trials is shifting analytical focus from metabolic substrates to direct measures of neuronal health. Validating neuroprotection is becoming essential for therapies targeting the neuronopathic phenotype, with neurofilament light chain providing a quantifiable metric of axonal damage that offers a more immediate readout of efficacy than longitudinal cognitive assessments. According to a February 2025 Nasdaq article, a Phase 1/2 study of tividenofusp alfa demonstrated a robust, sustained reduction in neurofilament light chain levels after a median follow-up of two years, confirming the utility of this biomarker in substantiating clinical value.

Key Market Players

• Takeda Pharmaceutical Co Ltd
• F Hoffmann-La Roche AG
• Abbott Laboratories Inc
• Johnson & Johnson
• GSK PLC
• Bayer AG
• Novartis AG
• Pfizer Inc
• Zimmer Biomet Holdings Inc
• Sangamo Therapeutics, Inc

Report Scope

In this report, the Global Hunter Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hunter Syndrome Treatment Market, By Treatment

• Enzyme Replacement Therapy
• Hematopoietic Stem Cell Transplant

Hunter Syndrome Treatment Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Hunter Syndrome Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hunter Syndrome Treatment Market.

Available Customizations:

Global Hunter Syndrome Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hunter Syndrome Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant)
  • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Hunter Syndrome Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hunter Syndrome Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Hunter Syndrome Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Hunter Syndrome Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By End User

7. Europe Hunter Syndrome Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hunter Syndrome Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By End User
  • 7.3.2. France Hunter Syndrome Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Hunter Syndrome Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Hunter Syndrome Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Hunter Syndrome Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By End User

8. Asia Pacific Hunter Syndrome Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hunter Syndrome Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By End User
  • 8.3.2. India Hunter Syndrome Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Hunter Syndrome Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Hunter Syndrome Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Hunter Syndrome Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By End User

9. Middle East & Africa Hunter Syndrome Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hunter Syndrome Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By End User
  • 9.3.2. UAE Hunter Syndrome Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By End User
  • 9.3.3. South Africa Hunter Syndrome Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By End User

10. South America Hunter Syndrome Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hunter Syndrome Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By End User
  • 10.3.2. Colombia Hunter Syndrome Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By End User
  • 10.3.3. Argentina Hunter Syndrome Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hunter Syndrome Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Takeda Pharmaceutical Co Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F Hoffmann-La Roche AG
• 15.3. Abbott Laboratories Inc
• 15.4. Johnson & Johnson
• 15.5. GSK PLC
• 15.6. Bayer AG
• 15.7. Novartis AG
• 15.8. Pfizer Inc
• 15.9. Zimmer Biomet Holdings Inc
• 15.10. Sangamo Therapeutics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer